do glp 1 agonists have cardiovascular benefit GLP-1 receptor improve health in type 2 diabetes GLP-1 Muscle Loss Explained |

Description

F.LewinA.SkjthT

Government healthcare policies and regulations regarding drug pricing and reimbursement play a critical role in determining the affordability and market penetration of GLP-1 receptor agonists

What did the study show

1 The LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome ResultsA Long-Term Evaluation), a large double-blind, placebo-controlled trial, recently demonstrated that liraglutide added to standard therapy for a relatively short period of time (3.5-5 years) had a significant reduction in cardiovas-cular events and mortality compared to placebo in high-risk patients (hazard ratio [HR], 0.87

Medications such as Ozempic (semaglutide), Wegovy and Mounjaro (tirzepatide) can be a life-changing option for many people living with type 2 diabetes or managing their weight